EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions to Participate in Investor Conferences

GAITHERSBURG, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences:

  • Goldman Sachs Credit and Leveraged Finance Conference

    May 17, 2021

    1-on-1 meetings only
  • Benchmark Company Healthcare House Call Conference

    May 26, 2021

    1-on-1 meetings only
  • Singular Research Spring Select Webcall

    May 27, 2021

    Company presentation scheduled at 8:00 am Pacific / 11:00 am Eastern

For conferences where a presentation is planned, the company’s webcast presentation may include a discussion of the company's recent business developments as well as its financial results and guidance. The webcast will be available both live, if possible, and by replay, and will be accessible from the .

About Emergent BioSolutions

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information, visit our and follow us on , , and .

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

  

Media Contact:

Matt Hartwig

Director, Media Relations



EN
05/05/2021

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New D...

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication  GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. T...

February 12, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Fina...

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via and also by visiting the page of Emergent’s website. To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive ...

February 12, 2026 1 EN
Free Trial
EBS Emergent BioSol...

Emergent Biosolutions Inc: 4 directors

Four Directors at Emergent Biosolutions Inc sold 89,428 shares at 10.920USD. The significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

EBS EMERGENT BIOSOLUTIONS INC.
02/11/26 February 11, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New D...

Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective way to reverse opioid overdoses, and today, new solutions like the NARCAN® carrying case aims to make accessibility paramount - ‘Trusted Then. Trusted Now’ GAITHERSBURG, Md., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions announced that the ...

January 14, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Prin...

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions, Inc. (NYSE: EBS) announced it made a voluntary prepayment of $100 million under its outstanding term loan facility in late December 2025 using cash on hand. “This significant milestone reflects strong progress in improving our overall financial/cash position, enhancing our financial flexibility and positioning Emergent for long-term stability and growth,” stated Joe P...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch